Changes in histological lesions and serum fibrogenesis markers in chronic hepatitis C patients non-responders to interferon alpha

Journal of Hepatology

Volumn 35, Issue 1, 2001, Pages 120-126

  Leroy, Vincent ^a   De Traversay, Caroline ^a   Barnoud, Raphaelle ^b   Hartmann, Jean Daniel ^c   Baud, Marilyne ^d   Ouzan, Denis ^e   Zarski, Jean Pierre ^a,d  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b Laboratory of Pathology   (France)

^c Lab Anat de Cytologie Pathologique   (France)

^d CNRS   (France)

^e INSTITUT ARNAULT TZANCK   (France)

Author keywords

Fibrosis; Hepatitis C virus; Hyaluronate; Interferon alpha; METAVIR; Peptide of type III procollagen

Indexed keywords

ALPHA INTERFERON; HYALURONIC ACID; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE;

ADULT; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FIBROGENESIS; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; HYALURONIC ACID; INTERFERON-ALPHA; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROCOLLAGEN; TREATMENT FAILURE;

EID: 0034947197     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(01)00091-5     Document Type: Article

References (32)

1. Long-term histologic improvement and loss of detectable intra-hepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon alpha therapy
2. Time course of histological changes in patients with a sustained biochemical and virological response to interferon-alpha therapy for chronic hepatitis C virus infection
3. Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment
4. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C
5. Modeling the impact of interferon alpha treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view
6. Effects of long-term administration of interferon alpha in two models of liver fibrosis in rats
7. The effect of interferon on the liver in chronic hepatitis C: A quantitative evaluation of histology by meta-analysis
8. Alpha-interferon in the treatment of chronic viral hepatitis: Effects on fibrogenesis serum markers
9. Randomized trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia
10. Changes in serum fibrogenesis markers during interferon therapy for chronic hepatitis type C
11. Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alpha
12. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
13. Inter- intra-observer variation in the assessment of liver biopsy of chronic hepatitis C
14. Natural history of liver fibrosis progression in patients with chronic hepatitis C
15. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
16. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
17. Interferon alpha 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
18. Persistence of a reduced collagen-producing phenotype in cultured scleroderma fibroblasts after short-term exposure to interferons
19. Interferon σ and γ inhibit proliferation and collagen synthesis of human Ito cells in culture
20. Alpha-interferon prevents liver collagen deposition and damage induced by prolonged bile duct obstruction in rats
21. Recombinant human alpha interferon in patients with chronic non-A, non-B hepatitis: A multicenter randomized controlled trial from France
22. Histollogically advanced chronic hepatitis C treated with recombinant alpha-interferon: A randomized placebo-controlled double-blind cross-over study
23. Treatment of chronic sporadic-type non-A, non-B hepatitis with lymphoblastoid interferon: Gamma GT levels predictive for response
24. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: A multicenter randomized controlled trial
25. Histopathological evaluation of liver fibrosis: Quantitative image analysis vs semi-quantitative scores
26. Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: Quantitative assessment by a morphometric method
27. Interferon alpha2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: A quantitative histological evaluation
28. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver
29. Serum type I collagen and N-terminal peptide of type III procollagen in chronic hepatitis
30. Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C
31. Correlation of biochemical response to interferon alpha with histological improvement in hepatitis C: A meta-analysis of diagnostic test characteristics
32. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration